Maze Therapeutics executive Bernstein Harold exercised Options covering 36,141 shares at prices ranging from $0 to $10.42 per share on 2026-09-01. He then sold 16,141 shares at $26.36 per share, leaving no directly owned shares while retaining 20,000 derivative securities, a change investors can track in his reported ownership.
Key Highlights
- The option exercises covered 36,141 derivative securities across two transactions.
- Bernstein Harold sold 16,141 shares at $26.36 per share on 1 September 2026.
- His reported holdings after the transactions included 20,000 derivative securities and zero shares.
Maze Therapeutics, Inc. (NASDAQ: MAZE) reported that Bernstein Harold exercised options covering 36,141 shares in two transactions on 1 September 2026. The exercises were priced from $0 to $10.42 per share, and the filing reports that the sale left Bernstein Harold with zero shares.
Two Option Exercises Cover 36,141 Shares
Bernstein Harold, Maze Therapeutics’ President, R&D and CMO, exercised options in two separate transactions on 1 September 2026. After those transactions, Bernstein Harold held 20,000 shares and 20,000 derivative securities of Maze Therapeutics.
Sale Sets Share Ownership at Zero
Bernstein Harold sold 16,141 Maze Therapeutics shares on the same date at $26.36 per share. Following that sale, his reported ownership of shares was zero. His reported derivative-security holdings remained at 20,000 after the option exercises.
FAQs
Q: What did Bernstein Harold do with Maze Therapeutics shares?
A: Bernstein Harold exercised options covering 36,141 shares and later sold 16,141 Maze Therapeutics shares at $26.36 per share on 1 September 2026.
Q: How many Maze Therapeutics shares does Bernstein Harold own after the sale?
A: Bernstein Harold’s reported ownership of Maze Therapeutics shares was zero after the sale. He held 20,000 derivative securities following the option exercises.
Q: What was the option exercise price for the Maze Therapeutics transaction?
A: The filing reports that the two option exercises covered 36,141 shares. They were priced from $0 to $10.42 per share on 1 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.